Catalent Pharma Solutions has completed the second phase of a $5.5-million expansion program at its Kansas City, Missouri facility to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business. This concludes a two-year project that also expanded the facility’s highly-potent, cytotoxic, and cold-storage clinical drug-packaging capabilities.

The latest expansion includes a new Drug Enforcement Administration Schedule I and II controlled substance vault, which provides the site with an additional 3,600 square feet of storage, as well as additional controlled-temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations. A new sampling room has been installed as well as a new emergency generator to help ensure the security and integrity of samples in storage.

Catalent’s 450,000-square-foot Kansas City facility provides integrated support services, from development and analytical support through to packaging and distribution. The expansions at Kansas City follow the recent announcements of new capabilities and capacity at two of Catalent’s other clinical supply facilities in Philadelphia, Pennsylvania and Singapore. In April 2018, Catalent completed a $5.5-million expansion at its more than 200,000-square-foot site Philadelphia to provide additional clinical packaging and storage capacity.

Source: Catalent Pharma Solutions